Khan, Samer Raza
Chaker, Layal
Ikram, Mohammad Arfan
Peeters, Robin Patrick
van Hagen, Petrus Martinus
Dalm, Virgil Alain Silvester Hovestadt
Funding for this research was provided by:
takeda pharmaceuticals u.s.a. (IIR-NLD-002671)
Article History
Received: 24 June 2021
Accepted: 6 August 2021
First Online: 10 September 2021
Declarations
:
: The authors declare no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Medical Ethics Committee of Erasmus University Medical Center (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272–159521-PG). The Rotterdam Study Personal Registration Data collection is filed with the Erasmus University Medical Center Data Protection Officer under registration number EMC1712001. The Rotterdam Study has been entered into the Netherlands National Trial Register and into the World Health Organization International Clinical Trials Registry Platform under shared catalogue number NTR6831.
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable as this study concerns population-based data with no identifying information about participants.